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Motivation: The lysosomal storage disorders (LSDs) conforms a group of over fifty monogenetic diseases characterized by 
the dysfunction of a lysosomal enzyme, frequently a glycosidase, and the subsequent accumulation of the corresponding 
substrate, which gives rise to several pathological manifestations. Individually they are rare diseases, but taken together they 
affect at 1 in 7,000 newborns. For some of these conditions enzyme replacement and/or substrate reduction therapeutic 
strategies (ERT and SRT, respectively) are available. Yet, most LSDs course with neurological deterioration and are refractory 
to ERT and SRT, remaining orphan diseases, sice the respective active principles are unable to cros the blood brain barrier 
(BBB). Ironically, in most of the LSD patients the causative mutation leads to the expression of a mutated ezyme that retains 
catalytic activity, but it is unable to properly fold at the endoplasmic reticulum (ER) and undertake the secretory pathway to the 
lysosome. Small molecules capable of promoting the correct folding and restore traficking, termed pharmacological 
chaperones (PCs), represents therefore a promising therapeutic option that is, in principle, better suited than ERT and SRT to 
target the neuronopathic forms.   
Methods: We have conducted research aiming at developing active site-directed pharmacologial chaperones for several LSDs 
based on glycomimetics (sugar lookaalikes). The molecular design implies a nitrogen-in-the-ring cycle bearing a hydroxylation 
profile that matches that of the monosaccharide cleave off by the target enzyme (Sánchez-Fernández et al. 2016). Such 
compounds can sit at the active site of the glycosidase, behaving as competitive inhibitors, subsequently inducing proper 
folding and trafficking. The chaperones are further elaborated to make them dissociate from the chaperone:enzyme complex at 
the lysosome, allowing substrate processing (Mena-Barragán et al. 2015). 
Results: PCs acting as glycosidase effectors in Gaucher, Fabry and GM1 gangliosidosis LSDs have been prepared based on 
the above concept. 
Conclusions: The ability of the PCs to cross the (BBB) and revert the accumulus of the substrate in the brain tissue (Takai et 
al. 2013) supports the promise of pharmacological chaperone therapy for a range of LSDs with neurological implications.  
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